August 3, 2017 / 8:55 PM / 2 years ago

BRIEF-Dynavax provides U.S. regulatory update on heplisav-b following FDA advisory committee meeting

Aug 3 (Reuters) - Dynavax Technologies Corp:

* Dynavax provides U.S. regulatory update on heplisav-b(tm) following fda advisory committee meeting

* Dynavax Technologies Corp - ‍FDA has requested more detailed information about company’s proposed post-marketing study for heplisav-b​

* Dynavax Technologies- ‍advisory committee voted 12 to 1 that safety data for heplisav-b support licensure for active immunization against hepatitis b ​

* Dynavax Technologies Corp - ‍Dynavax and FDA have discussed outcome of vrbpac meeting​

* Dynavax-Co,Fda agreed due to feedback provided,proximity to scheduled pdufa date,more time required to finalize key details of post-marketing study​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below